Reply to M.S. Aapro

[1]  M. Aapro.  Denosumab for bone metastases from breast cancer: a new therapy option? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Ray-Coquard,et al.  Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues , 2010, Breast Cancer Research and Treatment.

[4]  M. Widschwendter,et al.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer , 2010, Nature.

[5]  D. Branstetter,et al.  RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.

[6]  X. Mariette,et al.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Neary,et al.  The risk of renal impairment in hormone‐refractory prostate cancer patients with bone metastases treated with zoledronic acid , 2007, Cancer.

[8]  M. Krzakowski,et al.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Pazdur,et al.  Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  A. Howell,et al.  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.

[11]  V. Rose.  NCCN and ACS collaborate on a patient's version of the NCCN practice guidelines for breast cancer. National Comprehensive Cancer Network. American Cancer Society. , 1999, American family physician.

[12]  R. Slaughter,et al.  Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. , 1987, The American journal of medicine.

[13]  F. Ries,et al.  Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.